Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Ginkgo Bioworks Holdings, Inc. (DNA) had Consolidated Net Income/Loss of $-80.75M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$38.84M |
|
$-80.75M |
|
$12.80M |
|
$26.04M |
|
$128.85M |
|
$-90.02M |
|
$9.26M |
|
$-80.75M |
|
$-80.75M |
|
$-80.75M |
|
$-80.75M |
|
|
Consolidated Net Income/Loss |
$-80.75M |
$-80.75M |
|
$-90.02M |
|
$-75.85M |
|
55.63M |
|
55.63M |
|
$-1.45 |
|
$-1.45 |
|
| Balance Sheet Financials | |
$506.08M |
|
$176.58M |
|
$683.08M |
|
$1.19B |
|
$115.28M |
|
-- |
|
$514.10M |
|
$629.38M |
|
$559.78M |
|
$498.26M |
|
$559.78M |
|
56.84M |
|
| Cash Flow Statement Financials | |
$-123.38M |
|
$-335.39M |
|
$9.63M |
|
$605.74M |
|
$156.96M |
|
$-448.78M |
|
$60.52M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.39 |
|
-- |
|
-- |
|
-- |
|
-- |
|
67.04% |
|
-231.78% |
|
-231.78% |
|
-- |
|
-207.93% |
|
-207.93% |
|
$-131.04M |
|
-- |
|
-- |
|
-- |
|
0.03 |
|
-- |
|
1.74 |
|
51.81 |
|
-14.43% |
|
-16.21% |
|
-6.79% |
|
-14.43% |
|
$9.85 |
|
$-2.36 |
|
$-2.22 |
|